Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

NEUP

+ Watchlist+ Portfolio

Neuphoria Therapeutics Inc.

Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$2.27
52-Week Range
$2.26 – $5.53
Market Cap
$12.34M
P/E (TTM)
—
EPS (TTM)
-2.07
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.53
PEG Ratio
—
Return on Equity
-27.63%
Return on Assets
-12.82%
Gross Margin
100.00%
Operating Margin
-475.60%
Profit Margin
0.00%
Current Ratio
18.05
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-6.95M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$-6.41M

Market Snapshot

About

Neuphoria Therapeutics is a clinical-stage biopharmaceutical company developing novel treatments for neuropsychiatric disorders. The company focuses on innovative therapies for conditions such as depression, anxiety, and other mental health disorders using proprietary drug candidates and delivery mechanisms.